Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Infections and infestations – page 37

  • 677 clinical trials
  • 261 recruiting
  • 278 conditions
  • 27 countries

Conditions in this area

278 conditions with trials, the busiest first

HIV infection75COVID-1939Pneumonia32Sepsis29Influenza28Respiratory syncytial virus infection20Post-acute COVID-19 syndrome19Septic shock17Urinary tract infection17Chronic hepatitis B16Bacterial infection14Hepatitis D14Cytomegalovirus infection13Appendicitis10Hepatitis B10Pneumonia bacterial10Fungal infection9Irritable bowel syndrome8Medical device site joint infection8Pyelonephritis acute7Staphylococcal bacteraemia7Staphylococcal infection7T-cell type acute leukaemia7Lower respiratory tract infection6+254

Clinical trials in Infections and infestations

677 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

677 clinical trials

Chronic hepatitis C

Not recruiting

Comparing bemnifosbuvir-ruzasvir and sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in adult patients

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruzasvir
  • Sponsor:Atea Pharmaceuticals Inc.

HIV infection

Not recruiting

Study of MK-8527 taken once monthly compared to emtricitabine/tenofovir taken daily for HIV-1 prevention

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Merck Sharp & Dohme LLC

Influenza

Not recruiting

Study of mRNA-based seasonal influenza vaccine combinations compared to standard influenza vaccines in adults aged 18 and older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GSKVX000000034794
  • Sponsor:GlaxoSmithKline Biologicals

Pneumonia bacterial+1

Not recruiting

Study evaluating blood biomarkers for diagnosis and monitoring treatment in patients with pulmonary tuberculosis using isoniazid, rifampicin, pyrazinamide, and ethambutol combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Isoniazid
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz

Respiratory syncytial virus infection+1

Not recruiting

Studying the Effect of Nirsevimab Immunization on Antibody Development After RSV Infection in Healthy Infants

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · Healthy volunteers
  • Sponsor:Rijksinstituut voor Volksgezondheid en Milieu (RIVM)

Bronchopulmonary aspergillosis

Not recruiting

Effectiveness and Safety of Rezafungin in Adults with Chronic Pulmonary Aspergillosis Who Have Limited Treatment Options

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rezafungin Acetate
  • Sponsor:Mundipharma Research Limited

Influenza

Not recruiting

Live Attenuated Influenza Vaccine (LAIV) and Immune Response in the Nasopharynx of Young Children with Influenza

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · Healthy volunteers
  • Substances:INFLUENZA VIRUS B/AUSTRIA/1359417/2021 - LIKE STRAIN (B/AUSTRIA/1359417/2021, MEDI 355292)
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Hepatitis D

Not recruiting

Study on BJT-778 for Patients with Chronic Hepatitis Delta Infection

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bjt-778
  • Sponsor:Mirum Pharmaceuticals Inc.

Respiratory syncytial virus infection

Not recruiting

Study on the Effectiveness and Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:534
  • Sponsor:Sanofi Vaccines US Inc.

COVID-19

Not recruiting

Study on the Safety and Immune Response of PHH-1V81 Booster for Adults Vaccinated Against COVID-19

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Raxtozinameran
  • Sponsor:Hipra Scientific S.L.

Varicella

Not recruiting

Study on the Safety of a New Chickenpox Vaccine (GSKVX000000025896) Compared to Varicella Virus Oka/Merck Strain in Healthy Children Aged 12-15 Months

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

COVID-19

Not recruiting

Study on Immune Responses to COVID-19 Vaccines: Raxtozinameran, Bretovameran, and Drug Combination for COVID-19 Patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Elasomeran
  • Sponsor:Finnish Institute For Health And Welfare

Substances studied in this area

The therapies tested most often in Infections and infestations trials.

Sodium Chloride52 clinical trialsAmoxicillin35 clinical trialsEmtricitabine32 clinical trialsLinezolid32 clinical trialsTenofovir Alafenamide32 clinical trialsClavulanic Acid28 clinical trialsRifampicin25 clinical trialsSulfamethoxazole25 clinical trialsTrimethoprim25 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.